Literature DB >> 26135002

What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?

Pieter Julien Luc De Visschere1, Leslie Naesens2, Louis Libbrecht3, Charles Van Praet4, Nicolaas Lumen4, Valérie Fonteyne5, Eva Pattyn2, Geert Villeirs2.   

Abstract

OBJECTIVE: To analyse the characteristics of prostate cancers (PrCa) detected following negative multiparametric magnetic resonance imaging (mpMRI).
MATERIALS AND METHODS: Eight hundred and thirty patients with elevated prostate-specific antigen (mean 11.9 μg/l) underwent mpMRI of the prostate at 1.5 Tesla with endorectal coil. The characteristics of all PrCa detected within 2 years after a negative mpMRI were analysed. Primary Gleason grade 4 or any grade 5 PrCa were considered high-grade (HG), Gleason score 3 + 4 intermediate grade (IG) and Gleason score ≤3 + 3 low-grade (LG). Tumour size was considered 'small' when <1 cm on radical prostatectomy specimen or limited to ≤2 cores on prostate biopsy.
RESULTS: mpMRI was negative in 391 patients (47.1 %). In 124 patients (31.7 %) PrCa was detected within 2 years. Eighty-four (67.7 %) were LG, 22 (17.7 %) IG and 18 (14.5 %) HG. 119 (96.0 %) of the missed PrCa were organ-confined. The negative predictive value was 95.4 % (373/391) for HG PrCa. Among the 18 missed HG PrCa, 15 (83.3 %) were organ-confined and 12 (66.6 %) were small.
CONCLUSION: The majority of missed tumours on mpMRI were low grade and organ-confined. In patients with elevated PSA and a negative mpMRI, consideration could be given to continued surveillance rather than immediate biopsy. KEY POINTS: • The majority of missed prostate cancers were low grade and organ-confined. • In patients with a negative mpMRI a biopsy may be postponed. • mpMRI had a negative predictive value of 95.4 % for high-grade prostate cancer.

Entities:  

Keywords:  Diffusion magnetic resonance imaging; Magnetic resonance imaging; Magnetic resonance spectroscopy; Prostate; Prostatic neoplasms

Mesh:

Substances:

Year:  2015        PMID: 26135002     DOI: 10.1007/s00330-015-3894-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

Review 1.  Clinical and imaging tools in the early diagnosis of prostate cancer, a review.

Authors:  P De Visschere; W Oosterlinck; G De Meerleer; G Villeirs
Journal:  JBR-BTR       Date:  2010 Mar-Apr

2.  Mucinous adenocarcinoma of the prostate gland.

Authors:  J I Epstein; P H Lieberman
Journal:  Am J Surg Pathol       Date:  1985-04       Impact factor: 6.394

Review 3.  Active surveillance: patient selection.

Authors:  Laurence Klotz
Journal:  Curr Opin Urol       Date:  2013-05       Impact factor: 2.309

4.  Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected.

Authors:  Andrew B Rosenkrantz; Savvas Mendrinos; James S Babb; Samir S Taneja
Journal:  J Urol       Date:  2012-04-11       Impact factor: 7.450

Review 5.  How good is MRI at detecting and characterising cancer within the prostate?

Authors:  Alexander P S Kirkham; Mark Emberton; Clare Allen
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

6.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

7.  Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Authors:  James E Thompson; Daniel Moses; Ron Shnier; Phillip Brenner; Warick Delprado; Lee Ponsky; Marley Pulbrook; Maret Böhm; Anne-Maree Haynes; Andrew Hayen; Phillip D Stricker
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

8.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

Authors:  Deanna L Langer; Theodorus H van der Kwast; Andrew J Evans; Laibao Sun; Martin J Yaffe; John Trachtenberg; Masoom A Haider
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

9.  Analysis of cancers missed at screening mammography.

Authors:  R E Bird; T W Wallace; B C Yankaskas
Journal:  Radiology       Date:  1992-09       Impact factor: 11.105

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  16 in total

Review 1.  PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

Authors:  Anwar R Padhani; Jelle Barentsz; Geert Villeirs; Andrew B Rosenkrantz; Daniel J Margolis; Baris Turkbey; Harriet C Thoeny; François Cornud; Masoom A Haider; Katarzyna J Macura; Clare M Tempany; Sadhna Verma; Jeffrey C Weinreb
Journal:  Radiology       Date:  2019-06-11       Impact factor: 11.105

2.  Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis.

Authors:  Mengxia Chen; Qing Zhang; Chengwei Zhang; Xiaozhi Zhao; Giancarlo Marra; Jie Gao; Xiaoyu Lv; Bing Zhang; Yao Fu; Feng Wang; Xuefeng Qiu; Hongqian Guo
Journal:  J Nucl Med       Date:  2018-12-14       Impact factor: 10.057

3.  Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study.

Authors:  Raphaële Renard-Penna; Morgan Roupret; Eva Compérat; François Rozet; Benjamin Granger; Johann Barkatz; Marc Olivier Bitker; Olivier Lucidarme; Olivier Cussenot; Pierre Mozer
Journal:  World J Urol       Date:  2015-09-24       Impact factor: 4.226

Review 4.  Contemporary treatments in prostate cancer focal therapy.

Authors:  Michael Ahdoot; Amir H Lebastchi; Baris Turkbey; Bradford Wood; Peter A Pinto
Journal:  Curr Opin Oncol       Date:  2019-05       Impact factor: 3.645

5.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

Review 6.  Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer.

Authors:  Baris Turkbey; Anna M Brown; Sandeep Sankineni; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  CA Cancer J Clin       Date:  2015-11-23       Impact factor: 508.702

7.  What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.

Authors:  Samuel Borofsky; Arvin K George; Sonia Gaur; Marcelino Bernardo; Matthew D Greer; Francesca V Mertan; Myles Taffel; Vanesa Moreno; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2017-10-20       Impact factor: 11.105

8.  In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI.

Authors:  Kareem K Elfatairy; Christopher P Filson; Martin G Sanda; Adeboye O Osunkoya; Sherif G Nour
Journal:  Radiol Imaging Cancer       Date:  2019-11-29

Review 9.  Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound.

Authors:  Soleen Ghafoor; Daniel Stocker; Olivio F Donati; Hebert Alberto Vargas; Anton S Becker; Borna K Barth; Daniel Eberli
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 10.  Rethinking prostate cancer screening: could MRI be an alternative screening test?

Authors:  David Eldred-Evans; Henry Tam; Heminder Sokhi; Anwar R Padhani; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Urol       Date:  2020-07-21       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.